Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib helps long-term hair regrowth in severe alopecia areata patients.

Kidney cancer cells without folliculin are more sensitive to radiation due to increased self-eating cell death.

Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.

Blocking EGFR in skin cells doesn't majorly increase inflammation markers.

Baricitinib shows promise for treating alopecia areata with mild side effects.

Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

Partial hair-sparing brain radiotherapy is possible and doesn't affect cancer control but still causes noticeable hair loss.

Studying premature aging syndromes helps understand human aging and suggests potential treatments.

Erlotinib can cause scalp pustules and hair loss, needing early treatment with antibiotics and steroids.

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

A new compound shows promise as a topical treatment for hair loss.

JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.

Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.

Baricitinib works better than methotrexate for severe alopecia areata.

Certain genetic variants are linked to frontal fibrosing alopecia in Spanish patients.

Hair growth serums A and C can affect hair growth genes and pathways, suggesting potential for personalized hair loss treatments.

Anti-acne medications may work by reducing the activity of a protein involved in acne development.

The new Brigatinib nanocarrier is more effective against lung cancer cells than the free drug.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

Some patients on Baricitinib for alopecia areata lost response, often linked to longer and more severe initial conditions.

5α-Reductase inhibitors can help treat hair loss, acne, and prostate issues by reducing DHT levels.

A chemical called 5-Bromo-2′-deoxyuridine caused rapid hair loss in mice by killing certain skin cells through a specific cell death pathway.

Mononuclear cells may protect against certain chemotherapy-induced hair loss.

Specific mutations in a receptor cause facial abnormalities and hair loss.

Peptide nanoparticles can effectively deliver CRISPR-Cas9 to target KRAS mutations in cancer.

The treatments stopped hair regrowth in mice.

Men with early balding showed higher levels of certain genes linked to hair loss and possibly prostate cancer.

Tofacitinib effectively regrew scalp hair in an 11-year-old girl with alopecia areata.